1-4 of 4
Ming Lu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody–Drug Conjugate for Treatment of CLDN18.2-Positive Cancers

Neil A. O'Brien, Martina S.J. McDermott, Jun Zhang, Ke Wei Gong, Ming Lu, Benjamin Hoffstrom, Tong Luo, Raul Ayala, Kevin Chau, Min Liang, Athena M. Madrid, Timothy R. Donahue, John A. Glaspy, Leonard Presta, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12): 1365–1375.
https://doi.org/10.1158/1535-7163.MCT-23-0353
Published: 01 December 2023
View article titled, Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody–Drug Conjugate for Treatment of CLDN18.2-Positive Cancers
Open the PDF for Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody–Drug Conjugate for Treatment of CLDN18.2-Positive Cancers in another window
Includes: Supplementary data
Journal Articles

Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies

Neil A. O'Brien, Holly K.T. Huang, Martina S.J. McDermott, Athena M. Madrid, Tong Luo, Raul Ayala, Shawnt Issakhanian, Ke Wei Gong, Ming Lu, Jun Zhang, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (5): 751–761.
https://doi.org/10.1158/1535-7163.MCT-21-0847
Published: 04 May 2022
View article titled, Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies
Open the PDF for Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies in another window
Includes: Supplementary data
Journal Articles

Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Zhi Peng, Zhongwu Li, Jing Gao, Ming Lu, Jifang Gong, En-Tzu Tang, Kelly S. Oliner, Yong-Jiang Hei, Hui Zhou, Lin Shen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (11): 2634–2641.
https://doi.org/10.1158/1535-7163.MCT-15-0108
Published: 03 November 2015
View article titled, Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
Open the PDF for Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in another window
Includes: Supplementary data
Journal Articles

Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects

Sulma I. Mohammed, Deepika Dhawan, Shaji Abraham, Paul W. Snyder, David J. Waters, Bruce A. Craig, Ming Lu, Lan Wu, Rong Zheng, Jane Stewart, Deborah W. Knapp
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (2): 329–336.
https://doi.org/10.1158/1535-7163.MCT-05-0117
Published: 27 February 2006
View article titled, Cyclooxygenase inhibitors in urinary bladder cancer: <em>in vitro</em> and <em>in vivo</em> effects
Open the PDF for Cyclooxygenase inhibitors in urinary bladder cancer: <em>in vitro</em> and <em>in vivo</em> effects in another window